[ad_1]
South Africa received the first batch of the AstraZeneca vaccine last week – one million doses. Vaccinations are scheduled to begin in mid-January, but disappointing preliminary research suggests that the AstraZeneca vaccine may not live up to expectations.
A study, the results of which have not yet been published in a peer-reviewed journal, shows that the AstraZeneca vaccine ‘provides minimal protection against the development of a mild to moderate COVID-19 infection’ in young adults exposed to the spread of South Africa from coronavirus.
The University of Oxford and the University of Whitewater in Johannesburg stated in their report that protection against more severe forms of the disease could not be assessed because the study participants belonged to a low-risk group.
The new strain of coronavirus is considered more contagious and currently accounts for more than 90% of cases. In South Africa, the Minister of Health, Zweli Mkhize, reported new cases of infection on Sunday night.
It is not allowed to publish, quote or reproduce the information of the BNS news agency in the media and on websites without the written consent of the UAB “BNS”.
[ad_2]
